N/A
Completed N=26
ReShape Intragastric Balloon for the Treatment of Obesity
Source: ClinicalTrials.gov NCT01024465 ↗Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Sep 2015
Primary outcomePrimary: Total Weight Loss — -9.4 kg
Summary
A prospective, non-randomized, open-label, multi-center study designed to implant up to twenty-six (26) CE-marked ReShape™ Balloons in twenty-six (26) patients with body mass index (BMI) 30-40 to assess the effectiveness of the device. The RIB devices will be used within their labeled indications and as per their instructions for use. Enrolled patients will be followed for seven months. The patient will be prescribed a controlled diet, exercise and counseling. One group of 26 patients will receive treatment as follows: Placement, inflate to 900 cc, remove at 180 days, follow-up 30 days post removal (endoscopic video capture of placement and removal required).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Weight Loss |
-9.4 | — |
Eligibility Criteria
Inclusion Criteria
- The patient is male or female between the ages of 20 and 60 years of age.
- The patient presents with a Body Mass Index (BMI) 30-40 kg/m2.
- The patient is geographically stable and willing to return to the implant center for follow-up visits.
- The patient has been adequately informed of risks and requirements and consents to his/her participation in the post market clinical study.
Exclusion Criteria
- The patient presents with 20 years > Age > 60 years.
- The patient has a progressive disease, which in the Investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than 12 months.
- The patient is a pregnant or lactating female.
- The patient presents with a 30 kg/m2 > BMI > 40 kg/m2.
- The patient has had previous abdominal surgery.
- The patient has digestive tract disorders such as active peptic ulcers, bleeding disorders, esophageal varices, Crohn's disease.
- The patient presents with psychiatric disorders.
- The patient is participating in concomitant research studies of investigational products that would interfere with this study.
- The patient has inability to return for follow-up assessments.
- The patient is an alcohol or drug abuser.
Data sourced from ClinicalTrials.gov (NCT01024465). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.